Friday, 19 Jun 2020 02:00 pm

Reistone Announces First Patient Dosed in a Phase II Global Study of SHR0302 JAK Inhibitor for Alopecia Areata

"One of the most common treatments is corticosteroid either administered orally or as an injection. Oral corticosteroid has its side-effect while multiple injections to the scalp can cause significant pain, and is not acceptable to many," stated Dr. Min Irwin, Chief Executive Officer of Reistone, "We are very excited about the study and dosing the first subject, which represents another key milestone for Reistone as it marks the second phase II program in dermatology therapy area for this compound."

By Neha Pandey

Pro-nuclear energy protesters rally against Greenpeace in Paris

Credit Suisse taps Santangelo as global co-head of healthcare

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.